Clinical trials: SARS
Antiphospholipid Syndrome, COVID-19
Impact of Antiphospholipid Antibodies on Thrombin Generation During Sars-CoV2 Infection (TACIT2 Study)
Context: Until 70% of thrombotic event are reported during Sars-CoV2 infection. Antiphospholipid antibodies (aPL) tests are often positive.
- Trial name
- TACIT2 (NCT05128760)
- Testing
- characterization of aPL
- Where
- France
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Heathly Subjects Susceptible to SARS-CoV-2 Infection
Microbiome-Based Risk Prediction of SARS-CoV-2 in Children and Families (PREDICOL)
The goal of this observational cohort study is to evaluate the association between gut microbiota composition, dietary patterns, lifestyle-related factors, and neurodevelopmental outcomes, as well as susceptibility to SARS-CoV-2…
- Trial name
- PREDICOL (NCT07717008)
- Where
- Spain
- Volunteers
- 932 people, healthy volunteers welcome
- Sponsor
- Spanish National Research Council
SARS-COV 2, Covid19
Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19
This is an open-label, two arm interventional exploratory study to evaluate the safety and efficacy of 5-ALA-Phosphate-SFC during the vaccination of subjects against SARS-CoV-2 (COVID-19) virus infection to define the safety and…
- Trial name
- NCT04854876
- Testing
- 5-ALA-Phosphate + SFC (5-ALA+SFC)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years
The objective of this study is to evaluate the effectiveness of SCTV01E in participants aged ≥18 years.
- Trial name
- NCT05308576
- Testing
- SCTV01E
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Coronavirus
A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19
This study is a phase 1, open-label, randomized, first-in-human clinical trial to evaluate the safety, tolerability and reactogenicity of escalating doses of Baiya SARS-CoV-2 VAX1 vaccine in participants aged 18-60 for adult…
- Trial name
- NCT04953078
- Testing
- Baiya SARS-CoV-2 Vax 1
- Where
- 2 sites in Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Baiya Phytopharm Co., Ltd.
COVID-19
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Increased immune escape of emerging SARS-CoV-2 variants and waning neutralizing antibody levels over time indicate the importance of COVID-19 vaccine booster dose.
- Trial name
- NCT05716347
- Testing
- the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
SARS-CoV-2
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.
- Trial name
- NCT07266558
- Testing
- mRNA-1273, mRNA-1283
- Where
- 150 sites in United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Healthy
Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19
The primary objective of the study is to evaluate the safety and tolerability of REGN15160 in healthy participants, as measured by all treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events…
- Trial name
- NCT05293678
- Testing
- REGN15160 (IV), REGN15160 (SC)
- Where
- Belgium
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults
This is a multicenter, parallel groups, partially randomized, open-label, blank-controlled adaptive platform study to evaluate the effectiveness of a second COVID-19 vaccine booster in Chinese adults who are charactered as the…
- Trial name
- NCT05855408
- Testing
- Intramuscularly administered Ad5-nCoV vaccine, Aerosolized Ad5-nCoV, DelNS1-2019-nCoV-RBD-OPT1
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
SARS-CoV2 Infection
Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein
This is Phase 1 study is to assess tolerability and immunogenicity of three dose levels of the investigational HDT-301 vaccine administered intramuscularly (IM), both in immunization-naïve participants and as a booster for those…
- Trial name
- NCT05132907
- Testing
- HDT-301
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- HDT Bio
SARS-CoV-2
A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults
This study is a Phase I/II clinical study in healthy adults designed to assess the safety, tolerability, and immunogenicity of receiving 2 IM injections of Covigenix VAX-001/-1b, 28 days apart.
- Trial name
- NCT04591184
- Testing
- Covigenix VAX-001
- Where
- 4 sites in Burkina Faso, Canada and 2 more
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Entos Pharmaceuticals Inc.
Coronavirus, Covid19
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
The primary objective of this study is to evaluate the humoral immune response to CVnCoV in elderly adults aged ≥65 years and younger adults aged 18-45 years, 14 days after the second dose administration.
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04838847
- Testing
- CVnCoV Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- CureVac
COVID-19, SARS-CoV 2
Carrageenan Nasal Spray for COVID-19 Prophylaxis
The current COVID-19 pandemic is the biggest global healthcare challenge in the last century, and the number of cases in the next 12 months is likely to increase.
- Trial name
- ICE-COVID (NCT04590365)
- Testing
- Carrageenan nasal and throat spray, Saline nasal and throat spray
- Where
- United Kingdom
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Swansea University
Covid19
Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection
Prospective, cross-sectional study evaluating the effect of commercially available mouthwashes on expelled/exhaled SARS-CoV-2 viral load using face mask sampling.
- Trial name
- NCT04931004
- Testing
- Mouthwash Product
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
COVID-19
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19
This study is a randomized, double-blinded, and placebo-controlled phase Ia/IIa clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged 18~59 Years.
- Trial name
- NCT04412538
- Testing
- Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule, Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
- Where
- China
- Volunteers
- 942 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
COVID-19 Virus Infection
Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus
The purpose of the study is to assess safety and efficacy of Carnipure tartrate (L-Carnitine and L-tartaric acid - LCLT) supplementation for SARS-Cov-2 infection
- Trial name
- NCT05446961
- Testing
- LCLT : 68% elemental L-carnitine and 32 % Tartric acid
- Where
- Brazil
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- SENAI CIMATEC
SARS-CoV-2, Prevention
The Safety and Tolerability of MY-586 COVID-19 Neutralizing Antibody Nasal Spray in Healthy Subjects
This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 72 healthy subjects based on inclusion and exclusion criteria.
- Trial name
- NCT05977101
- Testing
- MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Coronavirus
A Study of Intranasal ChAdOx1 nCOV-19
Open label, dose escalation study to investigate: 1. Safety, tolerability and immunogenicity of one or two doses of intranasal ChAdOx1 nCOV-19, in vaccine naïve individuals, with randomisation between one and two dose groups. 2.
- Trial name
- NCT04816019
- Testing
- ChAdOx1 nCov-19
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19
Efficacy of Breathox Device Inhalation Therapy in the Treatment of Acute Symptoms Associated With COVID-19 and in the Prevention of the Use of Health Resources
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), the new coronavirus, causes a disease called COVID-19 that can trigger aggressive inflammatory responses.
- Trial name
- BREATH (NCT05196581)
- Testing
- Dispersible NaCl powder 10 sessions, Dispersible NaCl powder 5 sessions
- Where
- Brazil
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Suzana Erico Tanni Minamoto
Infection Viral
COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO)
There are still uncertainties about the existence of protective immunity and the duration of protective antibodies in patients infected with SARS-CoV-2.
- Trial name
- NCT04637867
- Testing
- Collection of blood, salivary and nasopharyngeal samples.
- Where
- 2 sites in France
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon